A suspected sugammadex-induced anaphylactic shock - A case report -A suspected sugammadex-induced anaphylactic shock - A case report -
- Other Titles
- A suspected sugammadex-induced anaphylactic shock - A case report -
- Authors
- 구본성; 이소정; 나현우; 강우빈; 김상현
- Issue Date
- 2019
- Publisher
- 대한마취통증의학회
- Keywords
- Anaphylaxis; Hypersensitivity; Sugammadex.
- Citation
- Anesthesia and Pain Medicine, v.14, no.3, pp 294 - 298
- Pages
- 5
- Journal Title
- Anesthesia and Pain Medicine
- Volume
- 14
- Number
- 3
- Start Page
- 294
- End Page
- 298
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/5080
- ISSN
- 1975-5171
2383-7977
- Abstract
- Background: The reversal of a neuromuscular blockade has typically been achieved with a cholinesterase inhibitor and the concomitant use of an anticholinergic agent, and this remains a popular method. Since the introduction of sugammadex in the market, its use has been increasing because of the rapid recovery from a neuromuscular blockade achieved by rocuronium. The occurrence of anaphylaxis or an anaphylactic reaction resulting from sugammadex is rare and has been reported sparsely. Thus, one may not recognize the possibility of sugammadex-induced hypersensitivity when sudden lifethreatening hypotension occurs, especially without skin manifestations during the emergence of anesthesia. This may delay treatment and increase morbidity.
Case: We report a case of a sugammadex-related hypersensitivity reaction which manifested as pure cardiovascular collapse during the emergence of anesthesia.
Conclusions: We emphasize that vigilance should be paid for at least five minutes following sugammadex administration in daily clinical practice.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Anesthesiology > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/5080)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.